Normoalbuminuric type 1 diabetic patients with retinopathy have an impaired tubular response to desmopressin: its relationship with plasma endothelin-1

What Was Tested

Researchers studied Vasopressin and Desmopressin in the context of diabetic retinopathy and glaucoma in this controlled clinical trial publication.

The aim of the study was to evaluate whether normoalbuminuric type 1 diabetic patients with diabetic retinopathy (DR) have an impaired tubular response to desmopressin (dDAVP, a synthetic analog of vasopressin) administration, and its relationship with plasma and urine endothelin-1 (ET-1) levels.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

Fifteen normoalbuminuric type 1 diabetic patients with DR were compared with 30 normoalbuminuric type 1 diabetic patients without DR.

How the Study Was Run

This was an interventional case-control study.

The study was conducted at a referral center.

Both groups were matched by age, gender, body mass index, glycosylated hemoglobin, and the main laboratory markers of kidney function.

Urine was collected at baseline and 1, 2, and 3 h after dDAVP administration.

ET-1 was assessed by ELISA.

What Was Measured

The subject headings attached to it are Albuminuria, Creatinine, Deamino Arginine Vasopressin, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Endothelin-1 and Kidney Tubules.

What This Means in Plain Language

This is a controlled clinical trial of Vasopressin and Desmopressin in people with diabetic retinopathy and glaucoma.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, Diabetic retinopathy and glaucoma research.